Skip to content
Menu

Kairos Pharma, Ltd. KAPA

Full chart Compare
Set alert

Price alert · KAPA

All alert types
0.41 USD -0.05 (-10.30%)

Regular-session close

0.43 +0.02 +5.63%

After hours · Nov 16, 5:05 PM ET

0.4069 Day range 0.4536
0.4069 52-week range 7.28
YTD
-91.81%
1 year
-92.98%
Market cap
1.38M
EPS (ttm)
-1.76
Shares out
12.85M
Forward P/E
-7.46
YTD return
-91.81%
1-year return
-92.98%
50-day average
1.54
Volume
12.72K
Avg volume
364.04K
Open
0.424
Previous close
0.4536
Day's range
0.4069 – 0.4536
52-week range
0.4069 – 7.28
Price target
9.00 (+2111.8%)

 

No chart data for this range yet.

Key statistics

200-day average
1.60
Enterprise value
17.13M
Free cash flow
-41.75K
Total cash
21.00K
Total debt
783.00K

Fundamental scorecard

6 of 25 checks passed on KAPA’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
KAPA Revenue — quarterly 0
KAPA Net income — quarterly -1.98M
KAPA EPS — quarterly -0.59

Upgrades / downgrades

KAPA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024D. Boral CapitalmainBuyBuy
Oct 14, 2024EF Huttoninit—Buy

About Kairos Pharma, Ltd.

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101 and 102, which are small molecules that are agonist and antagonist for the glucocorticoid induced TNF-like receptor ligand; KROS 201, an autologous T cell therapy targeting cancer stem cells of glioblastoma; KROS 301, a small molecule that targets the NF-?ß pathway, a cancer growth and immune suppressive molecule in triple negative breast cancer; and KROS 401, a cyclic peptide, which inhibits the IL-4 and IL-13 receptors. It also develops ENV 105, an antibody that targets CD105/Endoglin, which expressed in tumor cells and surrounding cells; and ENV 205, an antibody that targets mitochondrial DNA. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on KAPA — it syncs with the Stock Master app.

Institution ownership

KAPA institution ownership
Holder% heldSharesValueReported
Virtu Financial LLC0.25%32,71156.10KSep 29, 2024
HRT Financial LP0.10%12,60921.62KSep 29, 2024